Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish. In its six-month financial report for the ...

Eisai and Biogen have reported data showing that the benefit of treatment with their Alzheimer's disease therapy Leqembi appears to build over time, with no increase in safety risks. The results ...

Kisunla, along with two approved Alzheimer’s therapies from partners Biogen and Eisai, is part of a class of drugs that can also cause side effects like swelling and small-scale bleeding in the brain.

Kramer, M.D., FAAN, Chief Clinical Officer, Deep Human Biology Learning (DHBL), Eisai. “We are eager to engage in scientific exchange that will continue to advance neurology research and deepen our ...

1 Day ESAIY -1.53% DJIA -0.31% S&P 500 -1.12% Health Care/Life Sciences 0.63% ...

Seed Therapeutics, a BeyondSpring (Nasdaq: BYSI) spin-off, has inked a collaboration with Japan’s Eisai (TYO: 4523) to discover, develop and commercialize novel molecular glue degraders for multiple ...